Dengue disease
diseaseOn this page
Also known as break bone feverDengueDengue feverDengue virus caused disease or disorderDengue virus disease or disorderDengue virus infectionDengue virus infectious diseaseDFhemorrhagic denguePhilippine hemorrhagic feverSingapore hemorrhagic feverThai hemorrhagic fever
Summary
Dengue disease (MONDO:0005502) is a disease and 248 clinical trials. Top therapeutic interventions include emetine, ketotifen, and baricitinib. A subtype of Flaviviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 22
- Clinical trials: 248
Clinical features
Epidemiology
Prevalence records
25 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | >1 / 1000 | 714 | Worldwide | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.5 | Europe | Validated |
| Point prevalence | 1-9 / 100 000 | Europe | Validated | |
| Annual incidence | 1-9 / 100 000 | 1.14 | Austria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.98 | Belgium | Validated |
| Annual incidence | <1 / 1 000 000 | 0.033 | Croatia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.58 | Estonia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.98 | Finland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.36 | France | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.96 | Germany | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.14 | Hungary | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.32 | Ireland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.14 | Italy | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.34 | Latvia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.15 | Lithuania | Validated |
| Annual incidence | <1 / 1 000 000 | 0.04 | Luxembourg | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.22 | Malta | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.1 | Portugal | Validated |
| Annual incidence | <1 / 1 000 000 | 0.07 | Slovakia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.22 | Slovenia | Validated |
Signs & symptoms
Clinical features (HPO)
22 HPO clinical features (Orphanet curated; top 22 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0002315 | Headache | Very frequent (80-99%) |
| HP:0000988 | Skin rash | Frequent (30-79%) |
| HP:0000989 | Pruritus | Frequent (30-79%) |
| HP:0002027 | Abdominal pain | Frequent (30-79%) |
| HP:0002829 | Arthralgia | Frequent (30-79%) |
| HP:0000225 | Gingival bleeding | Occasional (5-29%) |
| HP:0000421 | Epistaxis | Occasional (5-29%) |
| HP:0000967 | Petechiae | Occasional (5-29%) |
| HP:0000978 | Bruising susceptibility | Occasional (5-29%) |
| HP:0001254 | Lethargy | Occasional (5-29%) |
| HP:0001342 | Cerebral hemorrhage | Occasional (5-29%) |
| HP:0001541 | Ascites | Occasional (5-29%) |
| HP:0001873 | Thrombocytopenia | Occasional (5-29%) |
| HP:0001882 | Leukopenia | Occasional (5-29%) |
| HP:0002014 | Diarrhea | Occasional (5-29%) |
| HP:0002017 | Nausea and vomiting | Occasional (5-29%) |
| HP:0002239 | Gastrointestinal hemorrhage | Occasional (5-29%) |
| HP:0002240 | Hepatomegaly | Occasional (5-29%) |
| HP:0002615 | Hypotension | Occasional (5-29%) |
| HP:0003075 | Hypoproteinemia | Occasional (5-29%) |
| HP:0006543 | Cardiorespiratory arrest | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | dengue disease |
| Mondo ID | MONDO:0005502 |
| EFO | EFO:0005547 |
| MeSH | D003715 |
| Orphanet | 99828 |
| DOID | DOID:12205 |
| ICD-10-CM | A90 |
| NCIT | C34528 |
| SNOMED CT | 38362002 |
| UMLS | C0011311 |
| MedGen | 3721 |
| GARD | 0006254 |
| MedDRA | 10012310 |
| Is cancer (heuristic) | no |
Also known as: break bone fever · Dengue · Dengue fever · Dengue virus caused disease or disorder · Dengue virus disease or disorder · Dengue virus infection · Dengue virus infectious disease · DF · hemorrhagic dengue · Philippine hemorrhagic fever · Singapore hemorrhagic fever · Thai hemorrhagic fever
Disease family
An umbrella term covering 2 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Flaviviridae infectious disease › dengue disease
Related subtypes (9): Powassan encephalitis, Murray valley encephalitis, West Nile fever, pestivirus infectious disease, st. Louis encephalitis, Kyasanur forest disease, Omsk hemorrhagic fever, Zika virus infectious disease, yellow fever
Subtypes (2): asymptomatic dengue, Dengue hemorrhagic fever
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Chimeric Yellow Fever Dengue Virus, Live Attenuated | Approved (phase 4) |
| Dengue Virus, Live Attenuated | Approved (phase 4) |
| Diphtheria Toxoid | Phase 3 (in late-stage trials) |
| Pertussis Vaccine Adsorbed | Phase 3 (in late-stage trials) |
| Tetanus Toxoid | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ivermectin, Melatonin, Zanamivir.
Clinical trials & evidence
Clinical trials
Clinical trials: 248.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 109 |
| PHASE2 | 47 |
| PHASE1 | 47 |
| PHASE3 | 26 |
| PHASE1/PHASE2 | 9 |
| PHASE2/PHASE3 | 6 |
| EARLY_PHASE1 | 3 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02673840 | PHASE4 | UNKNOWN | Ketotifen as a Treatment for Vascular Leakage During Dengue Fever |
| NCT06579755 | PHASE3 | RECRUITING | A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) |
| NCT06665035 | PHASE3 | RECRUITING | A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers |
| NCT06747130 | PHASE2/PHASE3 | RECRUITING | Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients |
| NCT06891950 | PHASE3 | RECRUITING | Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) |
| NCT06973772 | PHASE3 | NOT_YET_RECRUITING | Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. |
| NCT07016321 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) |
| NCT07047521 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults |
| NCT07543458 | PHASE3 | NOT_YET_RECRUITING | Therapeutics for Moderate and Severe Dengue |
| NCT07576868 | PHASE2/PHASE3 | RECRUITING | A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) |
| NCT00938379 | PHASE3 | UNKNOWN | Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR |
| NCT01134263 | PHASE3 | COMPLETED | Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia |
| NCT01254422 | PHASE3 | COMPLETED | Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia |
| NCT01373281 | PHASE3 | COMPLETED | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia |
| NCT01374516 | PHASE3 | COMPLETED | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America |
| NCT01411241 | PHASE3 | COMPLETED | Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers |
| NCT01436396 | PHASE3 | COMPLETED | Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers |
| NCT02045069 | PHASE2/PHASE3 | UNKNOWN | Efficacy and Safety of Ivermectin Against Dengue Infection |
| NCT02406729 | PHASE3 | UNKNOWN | Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine |
| NCT02979535 | PHASE3 | COMPLETED | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® |
| NCT02992418 | PHASE3 | TERMINATED | Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects |
| NCT02993757 | PHASE3 | COMPLETED | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® |
| NCT03341637 | PHASE3 | COMPLETED | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) |
| NCT03342898 | PHASE3 | COMPLETED | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults |
| NCT03423173 | PHASE3 | COMPLETED | Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue |
| NCT03771963 | PHASE3 | COMPLETED | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults |
| NCT03999996 | PHASE3 | COMPLETED | Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose |
| NCT04076254 | PHASE3 | UNKNOWN | Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever |
| NCT04313244 | PHASE3 | COMPLETED | Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years |
| NCT04673422 | PHASE2/PHASE3 | COMPLETED | Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients |
| NCT06121934 | PHASE3 | COMPLETED | Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial |
| NCT06741683 | PHASE2/PHASE3 | COMPLETED | A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan |
| NCT06744777 | PHASE3 | COMPLETED | The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever |
| NCT04597437 | PHASE2 | RECRUITING | Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) |
| NCT05229354 | PHASE2 | ACTIVE_NOT_RECRUITING | Dengue Controlled Human Infection Model in Dhaka, Bangladesh |
| NCT05611710 | PHASE2 | ACTIVE_NOT_RECRUITING | Anakinra in Dengue With Hyperinflammation ( AnaDen ) |
| NCT06006559 | PHASE2 | RECRUITING | A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever |
| NCT06551844 | PHASE2 | RECRUITING | Adaptive Dengue Antiviral Platform Trial |
| NCT06917001 | PHASE2 | NOT_YET_RECRUITING | Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) |
| NCT07172100 | PHASE2 | ENROLLING_BY_INVITATION | To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| EMETINE | 4 | 3 |
| KETOTIFEN | 4 | 3 |
| BARICITINIB | 4 | 1 |
| CHLOROQUINE | 4 | 1 |
| PERMETHRIN | 4 | 1 |
| REMDESIVIR | 4 | 1 |
| TETANUS TOXOID | 4 | 1 |
| ZANAMIVIR | 4 | 1 |
| MOLNUPIRAVIR | 3 | 1 |
| YELLOW FEVER VACCINE | 3 | 1 |
| CELGOSIVIR | 2 | 2 |
| MOSNODENVIR | 2 | 2 |
| BALAPIRAVIR | 2 | 1 |
| IC14 | 2 | 1 |
| MODIPAFANT | 2 | 1 |
| QUISOVALIMAB | 2 | 1 |
| RESOMELAGON | 2 | 1 |
| CHEMBL443232 | 0 | 2 |
| CHEMBL5427854 | 0 | 1 |
| CHEMBL5435500 | 0 | 1 |
| CHEMBL4061258 | 0 | 1 |
| CHEMBL5094495 | 0 | 1 |
| CHEMBL5280654 | 0 | 1 |
| CHEMBL5407656 | 0 | 1 |
| CHEMBL5430294 | 0 | 1 |
| CHEMBL5434013 | 0 | 1 |
| CHEMBL6143911 | 0 | 1 |
| CHEMBL4440558 | 0 | 1 |